Kinvard Bio is committed to developing a new, highly differentiated class of ribosome-targeting antibiotics to treat the most challenging acute and chronic drug-resistant bacterial infections.
Our chemistry platform technology is based on groundbreaking research that has been exclusively licensed from the Myers lab in the Department of Chemistry and Chemical Biology at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I).
The oxepanoprolinamides (OPPs) represent a distinct class of lincosamide antibiotics that are pre-organized for highly effective and differentiated binding to the bacterial ribosome. In preclinical studies, OPPs have proven effective against both Gram-positive and Gram-negative bacterial pathogens associated with high unmet clinical need and commercial potential.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Raleigh, North Carolina, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.kinvardbio.com
- HQ
- Raleigh, North Carolina
Kinvard Bio Questions
Kinvard Bio's website is http://www.kinvardbio.com
Kinvard Bio's LinkedIn profile is https://www.linkedin.com/company/kinvard-bio
Kinvard Bio has
7 employees.
View email and phone details for 7
employees at Kinvard Bio.
Kinvard Bio's industry is
Biotechnology Research
Kinvard Bio's top competitors are
North Carolina Biotechnology Center (Ncbiotech),
Kincell Bio,
Carb-X,
Inceptor Bio,
Achira,
Kineticos Life Sciences,
Arivin Therapeutics,
Summit Therapeutics, Inc.,
Hula Therapeutics,
Reverb Therapeutics.
Kinvard Bio's categories are Biotechnology Research
Kinvard Bio's founding year is 2024
